The total transaction value is estimated at over $500 million of which approximately 1/3 will be attributable to a 15-year manufacturing agreement and the expected value of developing and scaling new molecules.
The parties expect that the combination of DSM’s market reach and Amyris’s proprietary synthetic biology and fermentation platform will accelerate the industry’s transition to clean, sustainable chemistry.
Image: Amyris
